slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
230,851-230,880 of 319,975
10
Markforged | Results Presentation Deck | 21 slidesMarkforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Rising Success1 hit
11
The slide uses a logo-grid layout categorized by industry.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Rising Success1 hit
12
The slide uses a central product image with callouts pointing to specific features.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
13
The slide uses a before/after style logic to present the ROI and cost savings.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
14
The slide uses a linear process flow diagram to represent growth drivers.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
15
The slide uses a grid layout to display 11 executive profiles.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · The Breakthrough1 hit
16
The slide uses a grouped bar chart format to compare year-over-year performance for each quarter.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · The Breakthrough1 hit
17
The slide uses a dark theme with yellow and white bars to distinguish between 2022 and 2023 data.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
18
The slide uses a dark background with yellow text for key metrics. It includes specific disclaimers regarding non-GAAP reporting and revenue guidance basis.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
19
Includes a footnote explaining the composition of non-recurring costs for both years.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
20
Includes footnote detailing non-recurring costs.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
21
The slide is purely visual, serving as a title or transition page.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
02
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
03
The slide uses a process-flow structure to connect the technology (LNCs) to current clinical validation (MAT2203) and future pipeline expansion.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
04
Includes scientific illustration of molecular structure and bulleted list of key benefits.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
05
The slide uses a two-part framework to explain the biological mechanism: Targeting (left) and Delivery (right).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
06
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
07
Uses authority-citation to establish the urgency of the problem.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
08
Uses a before-after-bridge style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
This is a validation slide showing scientific credibility through peer-reviewed publication.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
11
The slide uses a human silhouette as a central anchor to map specific medical conditions to anatomical locations.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
12
Highlights clinical success in patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Includes a timeline of clinical events and longitudinal charts for Creatinine and Potassium levels.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
14
The slide highlights the limitations of current first-line azole treatments and identifies a specific patient sub-segment with high unmet need.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Mentions specific regulatory pathways (LPAD, QIDP, ODD, Fast-Track) and the ORALTO trial.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
16
The slide outlines a non-inferiority trial design comparing oral MAT2203 to IV LAMB/SoC.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
Uses a combination of an additive equation for the value prop and a chevron-based timeline for lifecycle management.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
18
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit